nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—asthma—chronic obstructive pulmonary disease	0.226	1	CtDrD
Salbutamol—Adrenergic beta2-Agonists—Arformoterol—chronic obstructive pulmonary disease	0.198	0.5	CiPCiCtD
Salbutamol—Adrenergic beta2-Agonists—Formoterol—chronic obstructive pulmonary disease	0.198	0.5	CiPCiCtD
Salbutamol—ADRB2—chronic obstructive pulmonary disease	0.111	1	CbGaD
Salbutamol—Isoprenaline—Formoterol—chronic obstructive pulmonary disease	0.0486	0.5	CrCrCtD
Salbutamol—Isoprenaline—Arformoterol—chronic obstructive pulmonary disease	0.0486	0.5	CrCrCtD
Salbutamol—ADRB2—Arformoterol—chronic obstructive pulmonary disease	0.0288	0.222	CbGbCtD
Salbutamol—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0288	0.222	CbGbCtD
Salbutamol—ADRB1—Formoterol—chronic obstructive pulmonary disease	0.0283	0.219	CbGbCtD
Salbutamol—ADRB1—Arformoterol—chronic obstructive pulmonary disease	0.0283	0.219	CbGbCtD
Salbutamol—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.00409	0.0315	CbGbCtD
Salbutamol—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0039	0.0301	CbGbCtD
Salbutamol—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00348	0.0268	CbGbCtD
Salbutamol—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00204	0.0157	CbGbCtD
Salbutamol—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00193	0.0149	CbGbCtD
Salbutamol—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00018	0.0811	CbGpPWpGaD
Salbutamol—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00016	0.0717	CbGpPWpGaD
Salbutamol—ADRB1—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.000147	0.066	CbGpPWpGaD
Salbutamol—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00013	0.0586	CbGpPWpGaD
Salbutamol—Pirbuterol—ADRB2—chronic obstructive pulmonary disease	0.000124	0.0893	CrCbGaD
Salbutamol—Levobunolol—ADRB2—chronic obstructive pulmonary disease	0.000111	0.0796	CrCbGaD
Salbutamol—Terbutaline—ADRB2—chronic obstructive pulmonary disease	0.000101	0.0728	CrCbGaD
Salbutamol—Isoetarine—ADRB2—chronic obstructive pulmonary disease	9.77e-05	0.0701	CrCbGaD
Salbutamol—Carteolol—ADRB2—chronic obstructive pulmonary disease	9.43e-05	0.0677	CrCbGaD
Salbutamol—Clenbuterol—TNF—chronic obstructive pulmonary disease	9.15e-05	0.0657	CrCbGaD
Salbutamol—Salmeterol—ADRB2—chronic obstructive pulmonary disease	8.63e-05	0.0619	CrCbGaD
Salbutamol—Nadolol—ADRB2—chronic obstructive pulmonary disease	8.41e-05	0.0603	CrCbGaD
Salbutamol—Clenbuterol—ADRB2—chronic obstructive pulmonary disease	8.11e-05	0.0582	CrCbGaD
Salbutamol—Bupranolol—ADRB2—chronic obstructive pulmonary disease	8.02e-05	0.0575	CrCbGaD
Salbutamol—Clenbuterol—CYP1A1—chronic obstructive pulmonary disease	6.95e-05	0.0499	CrCbGaD
Salbutamol—Clenbuterol—CYP1A2—chronic obstructive pulmonary disease	6.71e-05	0.0481	CrCbGaD
Salbutamol—ADRB1—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	6.63e-05	0.0298	CbGpPWpGaD
Salbutamol—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	6.62e-05	0.0298	CbGpPWpGaD
Salbutamol—Phenylephrine—CYP1A2—chronic obstructive pulmonary disease	6.06e-05	0.0435	CrCbGaD
Salbutamol—ADRB1—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	5.19e-05	0.0233	CbGpPWpGaD
Salbutamol—ADRB1—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	5.14e-05	0.0231	CbGpPWpGaD
Salbutamol—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	5.08e-05	0.0228	CbGpPWpGaD
Salbutamol—ADRB1—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	4.82e-05	0.0217	CbGpPWpGaD
Salbutamol—ADRB1—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	4.64e-05	0.0208	CbGpPWpGaD
Salbutamol—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	4.39e-05	0.00118	CcSEcCtD
Salbutamol—Agitation—Arformoterol—chronic obstructive pulmonary disease	4.38e-05	0.00117	CcSEcCtD
Salbutamol—Agitation—Formoterol—chronic obstructive pulmonary disease	4.38e-05	0.00117	CcSEcCtD
Salbutamol—Tremor—Montelukast—chronic obstructive pulmonary disease	4.37e-05	0.00117	CcSEcCtD
Salbutamol—ADRB1—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	4.36e-05	0.0196	CbGpPWpGaD
Salbutamol—Insomnia—Tiotropium—chronic obstructive pulmonary disease	4.36e-05	0.00117	CcSEcCtD
Salbutamol—Angioedema—Arformoterol—chronic obstructive pulmonary disease	4.36e-05	0.00117	CcSEcCtD
Salbutamol—Angioedema—Formoterol—chronic obstructive pulmonary disease	4.36e-05	0.00117	CcSEcCtD
Salbutamol—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	4.33e-05	0.00116	CcSEcCtD
Salbutamol—Malaise—Arformoterol—chronic obstructive pulmonary disease	4.3e-05	0.00115	CcSEcCtD
Salbutamol—Malaise—Formoterol—chronic obstructive pulmonary disease	4.3e-05	0.00115	CcSEcCtD
Salbutamol—Agitation—Montelukast—chronic obstructive pulmonary disease	4.29e-05	0.00115	CcSEcCtD
Salbutamol—Angioedema—Montelukast—chronic obstructive pulmonary disease	4.27e-05	0.00114	CcSEcCtD
Salbutamol—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	4.24e-05	0.00114	CcSEcCtD
Salbutamol—Affect lability—Prednisolone—chronic obstructive pulmonary disease	4.22e-05	0.00113	CcSEcCtD
Salbutamol—Palpitations—Arformoterol—chronic obstructive pulmonary disease	4.21e-05	0.00113	CcSEcCtD
Salbutamol—Palpitations—Formoterol—chronic obstructive pulmonary disease	4.21e-05	0.00113	CcSEcCtD
Salbutamol—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	4.18e-05	0.00112	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	4.16e-05	0.00111	CcSEcCtD
Salbutamol—Cough—Formoterol—chronic obstructive pulmonary disease	4.16e-05	0.00111	CcSEcCtD
Salbutamol—Cough—Arformoterol—chronic obstructive pulmonary disease	4.16e-05	0.00111	CcSEcCtD
Salbutamol—Palpitations—Montelukast—chronic obstructive pulmonary disease	4.13e-05	0.00111	CcSEcCtD
Salbutamol—Constipation—Tiotropium—chronic obstructive pulmonary disease	4.12e-05	0.0011	CcSEcCtD
Salbutamol—Hypertension—Formoterol—chronic obstructive pulmonary disease	4.12e-05	0.0011	CcSEcCtD
Salbutamol—Hypertension—Arformoterol—chronic obstructive pulmonary disease	4.12e-05	0.0011	CcSEcCtD
Salbutamol—Cough—Montelukast—chronic obstructive pulmonary disease	4.07e-05	0.00109	CcSEcCtD
Salbutamol—Mood swings—Prednisolone—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—Urticaria—Aminophylline—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—Myalgia—Formoterol—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—Chest pain—Formoterol—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—Myalgia—Arformoterol—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—Arthralgia—Formoterol—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—Chest pain—Arformoterol—chronic obstructive pulmonary disease	4.06e-05	0.00109	CcSEcCtD
Salbutamol—ADRB1—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	4.06e-05	0.0182	CbGpPWpGaD
Salbutamol—Isoprenaline—ADRB2—chronic obstructive pulmonary disease	4.05e-05	0.0291	CrCbGaD
Salbutamol—Anxiety—Formoterol—chronic obstructive pulmonary disease	4.04e-05	0.00108	CcSEcCtD
Salbutamol—Anxiety—Arformoterol—chronic obstructive pulmonary disease	4.04e-05	0.00108	CcSEcCtD
Salbutamol—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	4.04e-05	0.00108	CcSEcCtD
Salbutamol—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	4.04e-05	0.00108	CcSEcCtD
Salbutamol—Discomfort—Formoterol—chronic obstructive pulmonary disease	4.01e-05	0.00107	CcSEcCtD
Salbutamol—Discomfort—Arformoterol—chronic obstructive pulmonary disease	4.01e-05	0.00107	CcSEcCtD
Salbutamol—Myalgia—Montelukast—chronic obstructive pulmonary disease	3.98e-05	0.00106	CcSEcCtD
Salbutamol—Arthralgia—Montelukast—chronic obstructive pulmonary disease	3.98e-05	0.00106	CcSEcCtD
Salbutamol—ADRB2—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	3.97e-05	0.0178	CbGpPWpGaD
Salbutamol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	3.97e-05	0.00106	CcSEcCtD
Salbutamol—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	3.97e-05	0.00106	CcSEcCtD
Salbutamol—Anxiety—Montelukast—chronic obstructive pulmonary disease	3.96e-05	0.00106	CcSEcCtD
Salbutamol—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	3.94e-05	0.00106	CcSEcCtD
Salbutamol—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	3.94e-05	0.0177	CbGpPWpGaD
Salbutamol—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	3.89e-05	0.00104	CcSEcCtD
Salbutamol—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	3.89e-05	0.00104	CcSEcCtD
Salbutamol—Oedema—Arformoterol—chronic obstructive pulmonary disease	3.89e-05	0.00104	CcSEcCtD
Salbutamol—Oedema—Formoterol—chronic obstructive pulmonary disease	3.89e-05	0.00104	CcSEcCtD
Salbutamol—Infection—Arformoterol—chronic obstructive pulmonary disease	3.87e-05	0.00104	CcSEcCtD
Salbutamol—Infection—Formoterol—chronic obstructive pulmonary disease	3.87e-05	0.00104	CcSEcCtD
Salbutamol—Epinephrine—TNF—chronic obstructive pulmonary disease	3.84e-05	0.0276	CrCbGaD
Salbutamol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	3.83e-05	0.00103	CcSEcCtD
Salbutamol—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	3.82e-05	0.00102	CcSEcCtD
Salbutamol—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	3.82e-05	0.00102	CcSEcCtD
Salbutamol—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	3.82e-05	0.00102	CcSEcCtD
Salbutamol—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	3.81e-05	0.00102	CcSEcCtD
Salbutamol—Oedema—Montelukast—chronic obstructive pulmonary disease	3.81e-05	0.00102	CcSEcCtD
Salbutamol—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	3.81e-05	0.00102	CcSEcCtD
Salbutamol—Tachycardia—Formoterol—chronic obstructive pulmonary disease	3.8e-05	0.00102	CcSEcCtD
Salbutamol—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	3.8e-05	0.00102	CcSEcCtD
Salbutamol—Infection—Montelukast—chronic obstructive pulmonary disease	3.79e-05	0.00101	CcSEcCtD
Salbutamol—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	3.78e-05	0.00101	CcSEcCtD
Salbutamol—Skin disorder—Formoterol—chronic obstructive pulmonary disease	3.78e-05	0.00101	CcSEcCtD
Salbutamol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	3.77e-05	0.00101	CcSEcCtD
Salbutamol—Norepinephrine—ADRB2—chronic obstructive pulmonary disease	3.75e-05	0.0269	CrCbGaD
Salbutamol—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	3.74e-05	0.001	CcSEcCtD
Salbutamol—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	3.74e-05	0.001	CcSEcCtD
Salbutamol—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	3.73e-05	0.000999	CcSEcCtD
Salbutamol—Skin disorder—Montelukast—chronic obstructive pulmonary disease	3.7e-05	0.000991	CcSEcCtD
Salbutamol—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	3.69e-05	0.000988	CcSEcCtD
Salbutamol—Hypotension—Arformoterol—chronic obstructive pulmonary disease	3.64e-05	0.000974	CcSEcCtD
Salbutamol—Hypotension—Formoterol—chronic obstructive pulmonary disease	3.64e-05	0.000974	CcSEcCtD
Salbutamol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	3.62e-05	0.000969	CcSEcCtD
Salbutamol—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	3.61e-05	0.000967	CcSEcCtD
Salbutamol—ADRB2—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	3.6e-05	0.0162	CbGpPWpGaD
Salbutamol—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	3.58e-05	0.000959	CcSEcCtD
Salbutamol—ADRB1—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	3.56e-05	0.016	CbGpPWpGaD
Salbutamol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	3.55e-05	0.000951	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	3.54e-05	0.000949	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	3.54e-05	0.000949	CcSEcCtD
Salbutamol—Insomnia—Formoterol—chronic obstructive pulmonary disease	3.52e-05	0.000943	CcSEcCtD
Salbutamol—Insomnia—Arformoterol—chronic obstructive pulmonary disease	3.52e-05	0.000943	CcSEcCtD
Salbutamol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	3.5e-05	0.000937	CcSEcCtD
Salbutamol—ADRB2—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	3.48e-05	0.0156	CbGpPWpGaD
Salbutamol—Isoprenaline—CYP1A1—chronic obstructive pulmonary disease	3.48e-05	0.025	CrCbGaD
Salbutamol—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	3.47e-05	0.00093	CcSEcCtD
Salbutamol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	3.47e-05	0.000929	CcSEcCtD
Salbutamol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	3.47e-05	0.000929	CcSEcCtD
Salbutamol—Somnolence—Formoterol—chronic obstructive pulmonary disease	3.46e-05	0.000926	CcSEcCtD
Salbutamol—Somnolence—Arformoterol—chronic obstructive pulmonary disease	3.46e-05	0.000926	CcSEcCtD
Salbutamol—Insomnia—Montelukast—chronic obstructive pulmonary disease	3.45e-05	0.000923	CcSEcCtD
Salbutamol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	3.42e-05	0.000917	CcSEcCtD
Salbutamol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	3.42e-05	0.000917	CcSEcCtD
Salbutamol—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	3.42e-05	0.000917	CcSEcCtD
Salbutamol—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	3.42e-05	0.0154	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	3.41e-05	0.0153	CbGpPWpGaD
Salbutamol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	3.41e-05	0.000914	CcSEcCtD
Salbutamol—Epinephrine—ADRB2—chronic obstructive pulmonary disease	3.41e-05	0.0244	CrCbGaD
Salbutamol—Injury—Prednisone—chronic obstructive pulmonary disease	3.39e-05	0.000908	CcSEcCtD
Salbutamol—Somnolence—Montelukast—chronic obstructive pulmonary disease	3.39e-05	0.000907	CcSEcCtD
Salbutamol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	3.38e-05	0.000905	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	3.36e-05	0.0009	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	3.36e-05	0.0009	CcSEcCtD
Salbutamol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	3.35e-05	0.000898	CcSEcCtD
Salbutamol—Fatigue—Arformoterol—chronic obstructive pulmonary disease	3.35e-05	0.000898	CcSEcCtD
Salbutamol—Fatigue—Formoterol—chronic obstructive pulmonary disease	3.35e-05	0.000898	CcSEcCtD
Salbutamol—ADRB2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	3.34e-05	0.015	CbGpPWpGaD
Salbutamol—Constipation—Arformoterol—chronic obstructive pulmonary disease	3.33e-05	0.000891	CcSEcCtD
Salbutamol—Constipation—Formoterol—chronic obstructive pulmonary disease	3.33e-05	0.000891	CcSEcCtD
Salbutamol—Pain—Formoterol—chronic obstructive pulmonary disease	3.33e-05	0.000891	CcSEcCtD
Salbutamol—Pain—Arformoterol—chronic obstructive pulmonary disease	3.33e-05	0.000891	CcSEcCtD
Salbutamol—Increased appetite—Prednisone—chronic obstructive pulmonary disease	3.32e-05	0.000888	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	3.29e-05	0.000881	CcSEcCtD
Salbutamol—Fatigue—Montelukast—chronic obstructive pulmonary disease	3.29e-05	0.00088	CcSEcCtD
Salbutamol—Pain—Montelukast—chronic obstructive pulmonary disease	3.26e-05	0.000873	CcSEcCtD
Salbutamol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	3.25e-05	0.000871	CcSEcCtD
Salbutamol—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	3.24e-05	0.000867	CcSEcCtD
Salbutamol—Rash—Aminophylline—chronic obstructive pulmonary disease	3.22e-05	0.000863	CcSEcCtD
Salbutamol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	3.22e-05	0.000863	CcSEcCtD
Salbutamol—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	3.21e-05	0.00086	CcSEcCtD
Salbutamol—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	3.21e-05	0.000859	CcSEcCtD
Salbutamol—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	3.21e-05	0.000859	CcSEcCtD
Salbutamol—Headache—Aminophylline—chronic obstructive pulmonary disease	3.2e-05	0.000858	CcSEcCtD
Salbutamol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	3.19e-05	0.000854	CcSEcCtD
Salbutamol—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	3.18e-05	0.000852	CcSEcCtD
Salbutamol—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	3.18e-05	0.000852	CcSEcCtD
Salbutamol—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	3.12e-05	0.000835	CcSEcCtD
Salbutamol—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	3.11e-05	0.014	CbGpPWpGaD
Salbutamol—Norepinephrine—CYP1A2—chronic obstructive pulmonary disease	3.1e-05	0.0223	CrCbGaD
Salbutamol—Urticaria—Arformoterol—chronic obstructive pulmonary disease	3.09e-05	0.000828	CcSEcCtD
Salbutamol—Urticaria—Formoterol—chronic obstructive pulmonary disease	3.09e-05	0.000828	CcSEcCtD
Salbutamol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	3.08e-05	0.000824	CcSEcCtD
Salbutamol—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	3.08e-05	0.000824	CcSEcCtD
Salbutamol—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	3.08e-05	0.000824	CcSEcCtD
Salbutamol—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	3.08e-05	0.000824	CcSEcCtD
Salbutamol—Affect lability—Prednisone—chronic obstructive pulmonary disease	3.07e-05	0.000821	CcSEcCtD
Salbutamol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	3.07e-05	0.000821	CcSEcCtD
Salbutamol—Rash—Tiotropium—chronic obstructive pulmonary disease	3.04e-05	0.000814	CcSEcCtD
Salbutamol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	3.04e-05	0.000813	CcSEcCtD
Salbutamol—Nausea—Aminophylline—chronic obstructive pulmonary disease	3.04e-05	0.000813	CcSEcCtD
Salbutamol—Urticaria—Montelukast—chronic obstructive pulmonary disease	3.03e-05	0.000811	CcSEcCtD
Salbutamol—Headache—Tiotropium—chronic obstructive pulmonary disease	3.02e-05	0.000809	CcSEcCtD
Salbutamol—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	3.01e-05	0.000807	CcSEcCtD
Salbutamol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	3.01e-05	0.000807	CcSEcCtD
Salbutamol—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	2.98e-05	0.000798	CcSEcCtD
Salbutamol—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	2.98e-05	0.0134	CbGpPWpGaD
Salbutamol—Irritability—Prednisone—chronic obstructive pulmonary disease	2.97e-05	0.000796	CcSEcCtD
Salbutamol—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	2.97e-05	0.000794	CcSEcCtD
Salbutamol—Mood swings—Prednisone—chronic obstructive pulmonary disease	2.95e-05	0.00079	CcSEcCtD
Salbutamol—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	2.87e-05	0.000768	CcSEcCtD
Salbutamol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	2.87e-05	0.000768	CcSEcCtD
Salbutamol—Nausea—Tiotropium—chronic obstructive pulmonary disease	2.86e-05	0.000767	CcSEcCtD
Salbutamol—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	2.86e-05	0.0129	CbGpPWpGaD
Salbutamol—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	2.84e-05	0.000759	CcSEcCtD
Salbutamol—ADRB1—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	2.83e-05	0.0127	CbGpPWpGaD
Salbutamol—Epinephrine—CYP1A2—chronic obstructive pulmonary disease	2.82e-05	0.0202	CrCbGaD
Salbutamol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	2.81e-05	0.000752	CcSEcCtD
Salbutamol—Asthenia—Formoterol—chronic obstructive pulmonary disease	2.79e-05	0.000748	CcSEcCtD
Salbutamol—Asthenia—Arformoterol—chronic obstructive pulmonary disease	2.79e-05	0.000748	CcSEcCtD
Salbutamol—Pruritus—Formoterol—chronic obstructive pulmonary disease	2.75e-05	0.000737	CcSEcCtD
Salbutamol—Pruritus—Arformoterol—chronic obstructive pulmonary disease	2.75e-05	0.000737	CcSEcCtD
Salbutamol—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	2.75e-05	0.0124	CbGpPWpGaD
Salbutamol—Asthenia—Montelukast—chronic obstructive pulmonary disease	2.73e-05	0.000732	CcSEcCtD
Salbutamol—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	2.71e-05	0.000726	CcSEcCtD
Salbutamol—Pruritus—Montelukast—chronic obstructive pulmonary disease	2.7e-05	0.000722	CcSEcCtD
Salbutamol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	2.66e-05	0.000713	CcSEcCtD
Salbutamol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	2.66e-05	0.000713	CcSEcCtD
Salbutamol—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	2.65e-05	0.00071	CcSEcCtD
Salbutamol—Sweating increased—Prednisone—chronic obstructive pulmonary disease	2.62e-05	0.000702	CcSEcCtD
Salbutamol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	2.61e-05	0.000698	CcSEcCtD
Salbutamol—Dizziness—Formoterol—chronic obstructive pulmonary disease	2.57e-05	0.000689	CcSEcCtD
Salbutamol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	2.57e-05	0.000689	CcSEcCtD
Salbutamol—Dizziness—Montelukast—chronic obstructive pulmonary disease	2.52e-05	0.000675	CcSEcCtD
Salbutamol—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	2.48e-05	0.0112	CbGpPWpGaD
Salbutamol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	2.47e-05	0.000663	CcSEcCtD
Salbutamol—Vomiting—Formoterol—chronic obstructive pulmonary disease	2.47e-05	0.000663	CcSEcCtD
Salbutamol—Rash—Arformoterol—chronic obstructive pulmonary disease	2.45e-05	0.000657	CcSEcCtD
Salbutamol—Rash—Formoterol—chronic obstructive pulmonary disease	2.45e-05	0.000657	CcSEcCtD
Salbutamol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	2.45e-05	0.000656	CcSEcCtD
Salbutamol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	2.45e-05	0.000656	CcSEcCtD
Salbutamol—Headache—Arformoterol—chronic obstructive pulmonary disease	2.44e-05	0.000653	CcSEcCtD
Salbutamol—Headache—Formoterol—chronic obstructive pulmonary disease	2.44e-05	0.000653	CcSEcCtD
Salbutamol—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	2.43e-05	0.000651	CcSEcCtD
Salbutamol—Vomiting—Montelukast—chronic obstructive pulmonary disease	2.42e-05	0.000649	CcSEcCtD
Salbutamol—Rash—Montelukast—chronic obstructive pulmonary disease	2.4e-05	0.000644	CcSEcCtD
Salbutamol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	2.4e-05	0.000643	CcSEcCtD
Salbutamol—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	2.4e-05	0.000642	CcSEcCtD
Salbutamol—Headache—Montelukast—chronic obstructive pulmonary disease	2.39e-05	0.000639	CcSEcCtD
Salbutamol—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	2.39e-05	0.0107	CbGpPWpGaD
Salbutamol—Angioedema—Prednisolone—chronic obstructive pulmonary disease	2.36e-05	0.000632	CcSEcCtD
Salbutamol—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	2.35e-05	0.00063	CcSEcCtD
Salbutamol—Malaise—Prednisolone—chronic obstructive pulmonary disease	2.33e-05	0.000624	CcSEcCtD
Salbutamol—Vertigo—Prednisolone—chronic obstructive pulmonary disease	2.32e-05	0.000621	CcSEcCtD
Salbutamol—Syncope—Prednisolone—chronic obstructive pulmonary disease	2.32e-05	0.00062	CcSEcCtD
Salbutamol—Nausea—Arformoterol—chronic obstructive pulmonary disease	2.31e-05	0.000619	CcSEcCtD
Salbutamol—Nausea—Formoterol—chronic obstructive pulmonary disease	2.31e-05	0.000619	CcSEcCtD
Salbutamol—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	2.27e-05	0.000608	CcSEcCtD
Salbutamol—Nausea—Montelukast—chronic obstructive pulmonary disease	2.26e-05	0.000606	CcSEcCtD
Salbutamol—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	2.26e-05	0.0102	CbGpPWpGaD
Salbutamol—Hypertension—Prednisolone—chronic obstructive pulmonary disease	2.23e-05	0.000597	CcSEcCtD
Salbutamol—Discomfort—Prednisolone—chronic obstructive pulmonary disease	2.17e-05	0.000582	CcSEcCtD
Salbutamol—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	2.17e-05	0.00058	CcSEcCtD
Salbutamol—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	2.16e-05	0.000577	CcSEcCtD
Salbutamol—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	2.12e-05	0.000567	CcSEcCtD
Salbutamol—Oedema—Prednisolone—chronic obstructive pulmonary disease	2.11e-05	0.000564	CcSEcCtD
Salbutamol—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	2.11e-05	0.000564	CcSEcCtD
Salbutamol—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	2.08e-05	0.00934	CbGpPWpGaD
Salbutamol—Shock—Prednisolone—chronic obstructive pulmonary disease	2.07e-05	0.000555	CcSEcCtD
Salbutamol—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	2.06e-05	0.000551	CcSEcCtD
Salbutamol—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	2.04e-05	0.000546	CcSEcCtD
Salbutamol—Flushing—Prednisone—chronic obstructive pulmonary disease	2e-05	0.000536	CcSEcCtD
Salbutamol—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	2e-05	0.00898	CbGpPWpGaD
Salbutamol—Angiopathy—Prednisone—chronic obstructive pulmonary disease	1.96e-05	0.000524	CcSEcCtD
Salbutamol—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	1.95e-05	0.000521	CcSEcCtD
Salbutamol—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	1.93e-05	0.000516	CcSEcCtD
Salbutamol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	1.91e-05	0.00051	CcSEcCtD
Salbutamol—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	1.89e-05	0.000507	CcSEcCtD
Salbutamol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	1.89e-05	0.000506	CcSEcCtD
Salbutamol—Malnutrition—Prednisone—chronic obstructive pulmonary disease	1.88e-05	0.000502	CcSEcCtD
Salbutamol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	1.87e-05	0.00841	CbGpPWpGaD
Salbutamol—Pain—Prednisolone—chronic obstructive pulmonary disease	1.8e-05	0.000483	CcSEcCtD
Salbutamol—ADRB1—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	1.8e-05	0.00809	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	1.76e-05	0.00792	CbGpPWpGaD
Salbutamol—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	1.74e-05	0.000466	CcSEcCtD
Salbutamol—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	1.74e-05	0.000465	CcSEcCtD
Salbutamol—Agitation—Prednisone—chronic obstructive pulmonary disease	1.72e-05	0.000462	CcSEcCtD
Salbutamol—Angioedema—Prednisone—chronic obstructive pulmonary disease	1.71e-05	0.000459	CcSEcCtD
Salbutamol—ADRB2—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	1.71e-05	0.00768	CbGpPWpGaD
Salbutamol—Malaise—Prednisone—chronic obstructive pulmonary disease	1.69e-05	0.000453	CcSEcCtD
Salbutamol—Vertigo—Prednisone—chronic obstructive pulmonary disease	1.69e-05	0.000451	CcSEcCtD
Salbutamol—Syncope—Prednisone—chronic obstructive pulmonary disease	1.68e-05	0.000451	CcSEcCtD
Salbutamol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	1.67e-05	0.000448	CcSEcCtD
Salbutamol—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	1.65e-05	0.000442	CcSEcCtD
Salbutamol—Hypertension—Prednisone—chronic obstructive pulmonary disease	1.62e-05	0.000434	CcSEcCtD
Salbutamol—Arthralgia—Prednisone—chronic obstructive pulmonary disease	1.6e-05	0.000428	CcSEcCtD
Salbutamol—Myalgia—Prednisone—chronic obstructive pulmonary disease	1.6e-05	0.000428	CcSEcCtD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	1.6e-05	0.00718	CbGpPWpGaD
Salbutamol—Anxiety—Prednisone—chronic obstructive pulmonary disease	1.59e-05	0.000426	CcSEcCtD
Salbutamol—Discomfort—Prednisone—chronic obstructive pulmonary disease	1.58e-05	0.000423	CcSEcCtD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	1.56e-05	0.00702	CbGpPWpGaD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	1.55e-05	0.00698	CbGpPWpGaD
Salbutamol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	1.55e-05	0.000416	CcSEcCtD
Salbutamol—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	1.53e-05	0.00041	CcSEcCtD
Salbutamol—Oedema—Prednisone—chronic obstructive pulmonary disease	1.53e-05	0.00041	CcSEcCtD
Salbutamol—Infection—Prednisone—chronic obstructive pulmonary disease	1.52e-05	0.000407	CcSEcCtD
Salbutamol—Shock—Prednisone—chronic obstructive pulmonary disease	1.51e-05	0.000403	CcSEcCtD
Salbutamol—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	1.5e-05	0.000402	CcSEcCtD
Salbutamol—Tachycardia—Prednisone—chronic obstructive pulmonary disease	1.49e-05	0.0004	CcSEcCtD
Salbutamol—Skin disorder—Prednisone—chronic obstructive pulmonary disease	1.49e-05	0.000398	CcSEcCtD
Salbutamol—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	1.48e-05	0.000396	CcSEcCtD
Salbutamol—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	1.47e-05	0.0066	CbGpPWpGaD
Salbutamol—Anorexia—Prednisone—chronic obstructive pulmonary disease	1.46e-05	0.000391	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	1.39e-05	0.000374	CcSEcCtD
Salbutamol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	1.39e-05	0.000373	CcSEcCtD
Salbutamol—Insomnia—Prednisone—chronic obstructive pulmonary disease	1.38e-05	0.000371	CcSEcCtD
Salbutamol—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	1.37e-05	0.000368	CcSEcCtD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.37e-05	0.00615	CbGpPWpGaD
Salbutamol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	1.35e-05	0.000361	CcSEcCtD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.34e-05	0.00601	CbGpPWpGaD
Salbutamol—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	1.33e-05	0.000357	CcSEcCtD
Salbutamol—Rash—Prednisolone—chronic obstructive pulmonary disease	1.33e-05	0.000356	CcSEcCtD
Salbutamol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	1.33e-05	0.000356	CcSEcCtD
Salbutamol—Fatigue—Prednisone—chronic obstructive pulmonary disease	1.32e-05	0.000354	CcSEcCtD
Salbutamol—Headache—Prednisolone—chronic obstructive pulmonary disease	1.32e-05	0.000354	CcSEcCtD
Salbutamol—Constipation—Prednisone—chronic obstructive pulmonary disease	1.31e-05	0.000351	CcSEcCtD
Salbutamol—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	1.26e-05	0.000338	CcSEcCtD
Salbutamol—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	1.25e-05	0.000335	CcSEcCtD
Salbutamol—Nausea—Prednisolone—chronic obstructive pulmonary disease	1.25e-05	0.000335	CcSEcCtD
Salbutamol—Urticaria—Prednisone—chronic obstructive pulmonary disease	1.22e-05	0.000326	CcSEcCtD
Salbutamol—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	1.21e-05	0.00546	CbGpPWpGaD
Salbutamol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	1.21e-05	0.000324	CcSEcCtD
Salbutamol—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	1.21e-05	0.000324	CcSEcCtD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	1.19e-05	0.00534	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	1.17e-05	0.00527	CbGpPWpGaD
Salbutamol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	1.13e-05	0.000302	CcSEcCtD
Salbutamol—Asthenia—Prednisone—chronic obstructive pulmonary disease	1.1e-05	0.000294	CcSEcCtD
Salbutamol—Pruritus—Prednisone—chronic obstructive pulmonary disease	1.08e-05	0.00029	CcSEcCtD
Salbutamol—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	1.07e-05	0.0048	CbGpPWpGaD
Salbutamol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	1.05e-05	0.000281	CcSEcCtD
Salbutamol—ADRB1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.04e-05	0.00468	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.02e-05	0.00458	CbGpPWpGaD
Salbutamol—Dizziness—Prednisone—chronic obstructive pulmonary disease	1.01e-05	0.000271	CcSEcCtD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	1e-05	0.0045	CbGpPWpGaD
Salbutamol—Vomiting—Prednisone—chronic obstructive pulmonary disease	9.74e-06	0.000261	CcSEcCtD
Salbutamol—Rash—Prednisone—chronic obstructive pulmonary disease	9.65e-06	0.000259	CcSEcCtD
Salbutamol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	9.65e-06	0.000258	CcSEcCtD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	9.63e-06	0.00433	CbGpPWpGaD
Salbutamol—Headache—Prednisone—chronic obstructive pulmonary disease	9.59e-06	0.000257	CcSEcCtD
Salbutamol—Nausea—Prednisone—chronic obstructive pulmonary disease	9.09e-06	0.000244	CcSEcCtD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.63e-06	0.00388	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	8.58e-06	0.00386	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	8.53e-06	0.00383	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.52e-06	0.00383	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	8.35e-06	0.00375	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	7.83e-06	0.00352	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	7.67e-06	0.00345	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	7.66e-06	0.00344	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	7.5e-06	0.00337	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.3e-06	0.00328	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.15e-06	0.00321	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7e-06	0.00314	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	6.71e-06	0.00301	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	6.63e-06	0.00298	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	6.56e-06	0.00295	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	6.54e-06	0.00294	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	6.49e-06	0.00292	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.15e-06	0.00277	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.08e-06	0.00273	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.89e-06	0.00265	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.84e-06	0.00262	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.76e-06	0.00259	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.71e-06	0.00257	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.35e-06	0.0024	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.23e-06	0.00235	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.17e-06	0.00232	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.11e-06	0.0023	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.11e-06	0.0023	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.06e-06	0.00227	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.04e-06	0.00227	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5e-06	0.00225	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.27e-06	0.00192	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.21e-06	0.00189	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.15e-06	0.00186	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.05e-06	0.00182	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.92e-06	0.00176	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.92e-06	0.00176	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.87e-06	0.00174	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.83e-06	0.00172	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.72e-06	0.00167	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.69e-06	0.00166	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.67e-06	0.00165	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.35e-06	0.00151	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.3e-06	0.00148	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.23e-06	0.00145	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.16e-06	0.00142	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.16e-06	0.00142	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.09e-06	0.00139	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.09e-06	0.00139	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3e-06	0.00135	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.99e-06	0.00134	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.93e-06	0.00132	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.89e-06	0.0013	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.82e-06	0.00127	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.62e-06	0.00118	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.56e-06	0.00115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.31e-06	0.00104	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.26e-06	0.00102	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.15e-06	0.000965	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.1e-06	0.000944	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.98e-06	0.00089	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.98e-06	0.00089	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.93e-06	0.000866	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.79e-06	0.000805	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.78e-06	0.000802	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.77e-06	0.000796	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.75e-06	0.000784	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.73e-06	0.000778	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.62e-06	0.000728	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.61e-06	0.000723	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.58e-06	0.000712	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.57e-06	0.000707	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.55e-06	0.000696	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.52e-06	0.000681	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.44e-06	0.000647	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.41e-06	0.000633	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.18e-06	0.000532	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.16e-06	0.00052	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.13e-06	0.000508	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.11e-06	0.000497	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.08e-06	0.000485	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.06e-06	0.000474	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.05e-06	0.000473	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.04e-06	0.000467	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.57e-07	0.00043	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	9.49e-07	0.000427	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.36e-07	0.000421	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.1e-07	0.000409	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.9e-07	0.0004	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.75e-07	0.000393	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.66e-07	0.000389	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.47e-07	0.00038	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.77e-07	0.000349	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.6e-07	0.000342	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.3e-07	0.000328	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.19e-07	0.000323	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.13e-07	0.000321	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.99e-07	0.000314	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.98e-07	0.000314	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.84e-07	0.000307	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.7e-07	0.000301	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.36e-07	0.000286	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.87e-07	0.000264	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.74e-07	0.000258	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.38e-07	0.000242	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.26e-07	0.000236	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	4.32e-07	0.000194	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	4.13e-07	0.000186	CbGpPWpGaD
